The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

Slides:

Advertisements

Similar presentations

Synergistic antitumor effect of anti-CD40/CpG and 14

Advertisements

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Volume 15, Issue 2, Pages (February 2007)

by Norman Nausch, Ioanna E

Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses William H.D. Hallett, Erik Ames, Maite.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Volume 15, Issue 3, Pages (March 2009)

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Volume 17, Issue 2, Pages (February 2009)

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Volume 26, Issue 1, Pages (January 2018)

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

TNFα is an important survival and growth signal for melanoma.

Vaccine MN confer protective innate and adaptive immunity.

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

BTK-activated signaling regulates PDAC tumorigenesis.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

PD-L1 is expressed in breast cancer.

Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E. MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

NSD2-mediated methylation of PTEN at K349 dictates cellular sensitivity to DNA-damaging agents. NSD2-mediated methylation of PTEN at K349 dictates cellular.

Antiangiogenic effects of PI3K inhibitor NVP-BKM120.

Inhibition of MCL1 reduces AML in an in vivo murine model.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Presentation transcript:

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. A, C57BL/6 mice were transferred with the splenocytes from PMEL-Thy1.1 mice, followed by gp100 peptide vaccination. Vaccinated mice received either vehicle, GSK2636771 (30 mg/kg/d), or BKM120 (60 mg/kg/d) for 5 days. After 30 days, mice were boosted with gp100 peptide vaccine. Schematic representation of vaccine and the PI3K inhibitor (PI3Ki) treatment protocol was shown. Thy1.1, a congenic marker for transferred PMEL-1 T cells, was used to determine the number of gp100-specific T cells in peripheral blood from vaccinated mice after the PI3K inhibitor treatment. B, analysis of the effect of GSK2636771 on protein signaling networks by RPPA. Melanoma was initiated in a group of Tyr:CreER;Ptenlox/lox; BrafV600E/+ mice. Mice with measurable tumors were randomly treated with either vehicle or GSK2636771 (30 mg/kg/d) for 5 days. Protein lysates from treated tumors were harvested. The heatmap demonstrates the changes in proteins differentially expressed in GSK2636771-treated tumors. C and D, Tyr:CreER; Ptenlox/lox; BrafV600E/+ mice with measureable tumors were randomly treated with either vehicle plus control antibody, GSK2636771 (30 mg/kg/d), anti–PD-1(100 μg), or the combination of both GSK2636771 and anti–PD-1. C, tumor size in each of the treatment groups. Tumor growth was monitored every 3 days. D, Kaplan–Meier survival curves of mice treated with GSK2636771 and/or anti–PD-1. Log-rank test demonstrates statistical significance (P < 0.05): control versus GSK2636771 or GSK2636771 + anti–PD-1; GSK2636771 versus GSK2636771 + anti–PD-1; anti–PD-1 versus GSK2636771 + anti–PD-1 (N = 4–8). E, the numbers of tumor-infiltrating T cells in mice treated with GSK2636771 and/or anti–PD-1. GSK2636771 and/or anti–PD-1 were used to treat mice bearing either a spontaneous tumor or a transplanted tumor as described in C and Supplementary Fig. S7D, respectively. Seven days after treatment, tumor tissues were harvested and weighed. Single-cell suspensions from tumor tissues were made for CD8 and CD4 staining. One-way ANOVA test demonstrates statistical significance (P < 0.05): GSK2636771 + anti–PD-1 versus control, GSK2636771, or anti–PD-1. *, P < 0.05 (N = 4–5). Weiyi Peng et al. Cancer Discov 2016;6:202-216 ©2016 by American Association for Cancer Research